about
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsCatastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.Purpura as the initial presentation for small-cell lung cancer.Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repressionHer2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrationsNicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activityGene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.Genomic aberrations in young and elderly breast cancer patients.Genomic DNA Copy Number Aberrations, Histological Diagnosis, Oral Subsite and Aneuploidy in OPMDs/OSCCs.Uncovering the genomic heterogeneity of multifocal breast cancer.Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer.Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancerThe effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer.Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors.DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial.Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.Transcriptomic and genomic features of invasive lobular breast cancer.CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.Genomic Characterization of Primary Invasive Lobular Breast Cancer.DNA aneuploidy relationship with patient age and tobacco smoke in OPMDs/OSCCs.Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerSequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes.Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.APO866 activity in hematologic malignancies: a preclinical in vitro study.Paralytic ileus and liver failure--an unusual presentation of advanced erythropoietic protoporphyria.Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma.Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromesRelevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab eraSqualene epoxidase as a promising metabolic target in cancer treatmentDevelopment of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinomaLymph node number, surface area and lymph node ratio are important prognostic indicators in neoadjuvant chemoradiotherapy treated rectal cancerClinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancerCorrection to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancerSchlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancerCirculating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
P50
Q24297639-CD4A783E-ED12-4940-92D5-2FED98914589Q30912415-82C6915D-7588-4AB5-B22B-A84EE536059DQ33384398-E48A639C-662E-4CDD-A0C7-0F57DEB2CCE8Q33528957-26E52025-57EE-408D-AA96-701EC50362C5Q33623561-7E93C284-7299-4CA0-8F24-329C463125B1Q33810500-4DD728CE-8EB3-4A2A-8741-EDE2FE370DE0Q34634272-109C9437-6E35-400E-8E52-384886AC1661Q35541507-6CC0F0A5-30A1-4C13-B02A-63FA503B6A72Q35807554-5F065351-DB83-431D-B249-3C57AEEC33F5Q35833553-A3175B2F-2563-43E9-B483-541F56EB5497Q36404728-9DB1A6F4-A234-4077-9EE5-AE1D2778C709Q36488282-CBCF3AD4-48B4-4776-A1C7-56D905488D34Q36499925-0D211E3B-691E-44A8-9CE0-E0F07ECBE1F9Q36621776-378C2455-189D-4E43-92BD-4668969E7899Q37427804-8F88C2FD-E1B5-44CA-BC78-E3434A4FA121Q37990057-A7CFD3B2-8B93-4547-9F13-D4BCB2167B94Q37990061-57F0D908-7C9C-41D3-966E-707C730398C7Q38848171-16A85990-B572-4454-8B98-5FF634B4EE2CQ38910834-0806DA76-41BE-4A6F-B460-35B4AD3E2E28Q39235715-3FDCF6C0-B60F-4B5D-BBB9-8C1F71921890Q39505275-C8712B33-2A12-44D8-A8C3-2714A91238B4Q39669468-BA6F9BB0-8D1A-41AB-BEDF-89C68A3F69E4Q40880815-83C4249E-257C-496D-9852-4D2F07B18EC8Q41635073-7E297D20-B355-4489-AC58-D0D589318C12Q42223681-8F71647E-DDA2-4B35-BCA4-CF921E963FB5Q43924430-CA9C3044-BB87-4AFA-803F-F9EDF9204FA4Q44514251-0D025EC4-8C7A-4955-8CA6-2FEF91A5F3C4Q45357282-616A6C0F-3D40-4EB2-B0CB-8F07F2C23DC7Q45982055-7D5834A0-FB36-4C76-A868-409E58F98A16Q46246597-ED10C4F5-694A-47A7-87C2-0776ABC92636Q54856495-DDDF8514-0A20-40CA-A952-06A02C4B3347Q56776209-27F8193E-709F-4F86-A1F2-AF60A764B3F5Q58234490-0BE89340-61D2-4B38-BF33-26E3F8EF6687Q88215930-36111144-BE85-4654-AB1F-68B9947326C8Q89547437-B9EC05FE-A8ED-45D9-A7AD-4B2D546A0E1BQ90286918-15446108-7500-4DAB-BBE1-85755BC0C906Q91617569-7FAE7461-2454-417B-9A64-C13CD32FAC3EQ91843278-F2DB5295-4A88-447C-B711-10E2CE39125CQ92923830-DEB2069F-8655-4A23-9DEC-1F6A7AD2F770Q94593624-A5776A06-FC56-42CA-8EC4-BAB0B18102B8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gabriele Zoppoli
@ast
Gabriele Zoppoli
@en
Gabriele Zoppoli
@es
Gabriele Zoppoli
@nl
type
label
Gabriele Zoppoli
@ast
Gabriele Zoppoli
@en
Gabriele Zoppoli
@es
Gabriele Zoppoli
@nl
prefLabel
Gabriele Zoppoli
@ast
Gabriele Zoppoli
@en
Gabriele Zoppoli
@es
Gabriele Zoppoli
@nl
P106
P1153
24382083200
P31
P496
0000-0002-1619-1708